Skip to content
value.today

Black Diamond Therapeutics, Inc.

BDTX
$108 Mmarket cap on Oct 26, 2026-23.4% since Jan 2024
Compare
World rank
#18,458
Revenue
$70 M
For year ending December-2025
Net income
$22 M
32.0% margin
SEC filing
Employees
31
As on January-2020
value.today research

Black Diamond Therapeutics, Inc. in brief

Black Diamond Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Cambridge, Massachusetts, USA. Its market value was $108 M on 26 October 2026, which makes it the 18,458th largest listed company in the world and the 3,482nd largest in the USA on this site. In the year to December 2025 it had sales of $70 M and a net profit of $22 M, about 32 cents of profit for every dollar of sales. It employs about 31 people and Mark A. Velleca is its chief executive. Its largest business segments by sales in 2025 were Reportable segment (100%). Its shares trade under the symbol BDTX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics is a Precision Oncology Medicine Company Pioneering the Discovery of Small Molecule and Tumor Agnostic Therapies. The company annual revenue is 154.7 million USD and 58 employees as on 2019. The headquarters is in USA.

Black Diamond Therapeutics, Inc. timeline

3 events, 2017–2020
  1. 2017
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2018
  4. ✎
    Renamed Black Diamond Therapeutics, Inc.
    Formerly Aset Therapeutics, Inc..
  5. 2020
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 30 January 2020; shares registered for exchange trading on 27 January 2020.

Events of Black Diamond Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$312 M$623 M$935 M$1.2 B202120222023202420252026

World rank over time

▼ down 11,124 places since 2021
2021-01-01: #7370#7,37020212022-01-07: #19192#19,19220222022-12-25: #25581#25,58120222023-07-30: #18486#18,48620232024-01-05: #19714#19,71420242026-03-08: #9682#9,68220262026-08-01: #16954#16,95420262026-10-14: #18938#18,93820262026-10-26: #18494#18,4942026

Rank in USA: #2,041 (Jan 2021) · #3,909 (Jan 2022) · #4,836 (Dec 2022) · #3,672 (Jul 2023) · #3,476 (Jan 2024) · #1,879 (Mar 2026) · #3,360 (Aug 2026) · #3,504 (Oct 2026) · #3,485 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
4.8×
Price / sales
1.5×
Price / book
1.0×
Free cash flow yield
-57.7%
Net margin
32.0%
Operating margin
17.9%
Return on equity
19.9%
Liabilities / assets
21.5%
R&D / revenue
47.9%
Revenue per employee
$2.3 M
Profit per employee
$722 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-9M—FY18Fiscal year ending Dec 2019: revenue —, net income $-35M—FY19Fiscal year ending Dec 2020: revenue —, net income $-67M—FY20Fiscal year ending Dec 2021: revenue —, net income $-126M—FY21Fiscal year ending Dec 2022: revenue —, net income $-91M—FY22Fiscal year ending Dec 2023: revenue —, net income $-82M—FY23Fiscal year ending Dec 2024: revenue —, net income $-70M—FY24Fiscal year ending Dec 2025: revenue $70M, net income $22M$70MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$70M—$13M$22M32.0%
Dec 2024——$-79M$-70M—
Dec 2023——$-86M$-82M—
Dec 2022——$-93M$-91M—
Dec 2021——$-127M$-126M—
Dec 2020——$-70M$-67M—
Dec 2019——$-29M$-35M—
Dec 2018——$-9M$-9M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$30M——$0.39—
Dec 2024$-62M$0M$-62M$-1.27—
Dec 2023$-67M$0M$-67M$-1.88—
Dec 2022$-85M$0M$-85M$-2.52—
Dec 2021$-100M$3M$-103M$-3.47—
Dec 2020$-52M$0M$-52M$-2.05—
Dec 2019$-25M$0M$-25M$-16.99—
Dec 2018$-8M$0M$-9M$-4.42—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-16M—Dec ’24Three months to Mar 2025: revenue $70M, net income $57M$70MMar ’25Three months to Jun 2025: revenue —, net income $-11M—Jun ’25Three months to Sep 2025: revenue —, net income $-9M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-15M—Dec ’25Three months to Mar 2026: revenue —, net income $-9M—Mar ’26Three months to Jun 2026: revenue —, net income $-10M—Jun ’26Three months to Sep 2026: revenue —, net income $-10M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-10M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Black Diamond Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$70 M
Operating income
$13 M
Net income
$22 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$143 M
Total liabilities
$31 M
Total equity
$112 M

As of December-2025

Top 100 institutional investors in Black Diamond Therapeutics, Inc.#

As of Sep 30, 2026
111 institutions held 37.8 M shares (about 65.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 43.6%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Black Diamond Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1NEA Management Company, LLC4,448,7570 (0.00%)7.74%$8 MNov 16, 2026
2BlackRock, Inc.4,300,642+383,554 (+9.79%)7.48%$8 MNov 13, 2026
3T. Rowe Price Investment Management, Inc.3,925,698-102,504 (-2.54%)6.83%$7 MNov 16, 2026
4Acadian Asset Management LLC2,348,6510 (0.00%)4.09%$4 MNov 9, 2026
5Vanguard Capital Management LLC2,125,2700 (0.00%)3.70%$4 MNov 13, 2026
6Bank Of America Corp /de/2,047,829+1,634,313 (+395.22%)3.56%$4 MNov 16, 2026
7Defilade Capital Management, L.P.1,770,948+95,949 (+5.73%)3.08%$3 MNov 16, 2026
8Renaissance Technologies LLC1,652,100-310,294 (-15.81%)2.87%$3 MNov 12, 2026
9Geode Capital Management, LLC1,246,314+28,143 (+2.31%)2.17%$2 MNov 6, 2026
10Marshall Wace, LLP1,176,357+279,755 (+31.20%)2.05%$2 MNov 13, 2026
11Connor, Clark & Lunn Investment Management Ltd.1,122,679+29,794 (+2.73%)1.95%$2 MNov 10, 2026
12Dimensional Fund Advisors LP955,804-409,580 (-30.00%)1.66%$2 MNov 4, 2026
13State Street Corp943,260+418,247 (+79.66%)1.64%$2 MNov 12, 2026
14AQR Capital Management LLC889,633New1.55%$2 MNov 16, 2026
15Morgan Stanley776,947+545,747 (+236.05%)1.35%$1 MNov 13, 2026
16FMR LLC746,339+102,671 (+15.95%)1.30%$1 MNov 10, 2026
17Bridgeway Capital Management, LLC735,304-56,130 (-7.09%)1.28%$1 MNov 16, 2026
18Goldman Sachs Group Inc687,545+398,765 (+138.09%)1.20%$1 MNov 16, 2026
19AWM Investment Company, Inc.650,000-350,000 (-35.00%)1.13%$1 MNov 13, 2026
20Vanguard Portfolio Management LLC414,847+7,773 (+1.91%)0.72%$1 MNov 13, 2026
21Northern Trust Corp361,550-3,844 (-1.05%)0.63%$1 MNov 16, 2026
22Empowered Funds, LLC358,809+110,675 (+44.60%)0.62%$1 MNov 13, 2026
23UBS Group AG345,978+80,665 (+30.40%)0.60%$1 MNov 10, 2026
24Vanguard Fiduciary Trust Co340,603+30,750 (+9.92%)0.59%$1 MNov 13, 2026
25Bank of New York Mellon Corp308,012-10,751 (-3.37%)0.54%$1 MNov 5, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Black Diamond Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Stifel Financial Corp289,425+8,180 (+2.91%)0.50%$1 MNov 12, 2026
27D. E. Shaw & Co., Inc.278,469+121,129 (+76.99%)0.48%$1 MNov 16, 2026
28O'shaughnessy Asset Management, LLC166,552-122,319 (-42.34%)0.29%$0 MNov 12, 2026
29Banque Cantonale Vaudoise147,221New0.26%$0 MNov 12, 2026
30Barclays PLC143,991+103,934 (+259.47%)0.25%$0 MNov 6, 2026
31Charles Schwab Investment Management Inc128,418+20,730 (+19.25%)0.22%$0 MNov 16, 2026
32Panagora Asset Management Inc124,496-170,676 (-57.82%)0.22%$0 MNov 12, 2026
33XTX Topco Ltd112,429+68,128 (+153.78%)0.20%$0 MNov 16, 2026
34BNP Paribas Financial Markets106,929+98,902 (+1232.12%)0.19%$0 MNov 12, 2026
35Canada Pension Plan Investment Board103,6000 (0.00%)0.18%$0 MNov 16, 2026
36RB Capital Management, LLC100,0000 (0.00%)0.17%$0 MNov 17, 2026
37Balyasny Asset Management L.P.87,313-454,859 (-83.90%)0.15%$0 MNov 16, 2026
38Ritholtz Wealth Management79,183-99,296 (-55.63%)0.14%$0 MNov 5, 2026
39American Century Companies Inc78,245-3,066 (-3.77%)0.14%$0 MNov 12, 2026
40Invesco Ltd.69,039-62,624 (-47.56%)0.12%$0 MNov 12, 2026
41Nuveen, LLC67,387+2,586 (+3.99%)0.12%$0 MNov 10, 2026
42Raymond James Financial Inc67,061+4,826 (+7.75%)0.12%$0 MNov 12, 2026
43SEI Investments Co58,314+18,631 (+46.95%)0.10%$0 MNov 10, 2026
44Los Angeles Capital Management LLC58,025New0.10%$0 MNov 12, 2026
45Jane Street Group, LLC51,291-238,421 (-82.30%)0.09%$0 MNov 12, 2026
46Two Sigma Investments, LP40,604-1,396 (-3.32%)0.07%$0 MNov 16, 2026
47Deutsche Bank AG\40,261-5,777 (-12.55%)0.07%$0 MNov 6, 2026
48Citigroup Inc40,133+16,997 (+73.47%)0.07%$0 MNov 4, 2026
49Price T Rowe Associates Inc /MD/39,2760 (0.00%)0.07%$0 MNov 16, 2026
50HSBC Holdings PLC37,542+11,121 (+42.09%)0.07%$0 MNov 16, 2026
51Ieq Capital, LLC37,491New0.07%$0 MNov 10, 2026
52Susquehanna International Group, LLP36,147+1,136 (+3.24%)0.06%$0 MNov 16, 2026
53Rhumbline Advisers35,383-1,412 (-3.84%)0.06%$0 MNov 10, 2026
54Alliancebernstein L.P.32,3400 (0.00%)0.06%$0 MNov 16, 2026
55Jpmorgan Chase & Co31,683+2,441 (+8.35%)0.06%$0 MNov 12, 2026
56Kestra Advisory Services, LLC31,200New0.05%$0 MNov 2, 2026
57Public Employees Retirement System Of Ohio30,396New0.05%$0 MNov 16, 2026
58New York State Common Retirement Fund30,3000 (0.00%)0.05%$0 MNov 17, 2026
59EFG International AG27,0000 (0.00%)0.05%$0 MNov 16, 2026
60Mariner, LLC25,718New0.04%$0 MNov 12, 2026
61Beacon Capital Management, LLC25,615+10,000 (+64.04%)0.04%$0 MOct 23, 2026
62Spark Investment Management LLC25,200+9,700 (+62.58%)0.04%$0 MNov 13, 2026
63MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.22,871+1,139 (+5.24%)0.04%$0 MNov 16, 2026
64Police & Firemen's Retirement System of New Jersey21,909-2,176 (-9.03%)0.04%$0 MNov 9, 2026
65Corient Private Wealth LP20,232New0.04%$0 MNov 16, 2026
66DLK Investment Management, LLC18,200+1,985 (+12.24%)0.03%$0 MOct 9, 2026
67Kathmere Capital Management, LLC18,149+7,901 (+77.10%)0.03%$0 MOct 20, 2026
68J. Safra Sarasin Holding AG17,145+1,645 (+10.61%)0.03%$0 MOct 26, 2026
69Mercer Global Advisors Inc /adv17,049New0.03%$0 MNov 16, 2026
70Vanguard Global Advisers, LLC15,850+183 (+1.17%)0.03%$0 MNov 13, 2026
71Quadrature Capital Ltd15,419-61,287 (-79.90%)0.03%$0 MNov 13, 2026
72Gsa Capital Partners LLP14,820-206,087 (-93.29%)0.03%$0 MNov 16, 2026
73LPL Financial LLC14,705-26,090 (-63.95%)0.03%$0 MNov 6, 2026
74Creative Planning11,329New0.02%$0 MNov 2, 2026
75China Universal Asset Management Co., Ltd.10,483+1,363 (+14.95%)0.02%$0 MOct 28, 2026
76Wells Fargo & Company/mn9,177-30,378 (-76.80%)0.02%$0 MNov 16, 2026
77Tower Research Capital LLC (TRC)7,254-2,693 (-27.07%)0.01%$0 MNov 16, 2026
78Nisa Investment Advisors, LLC4,9920 (0.00%)0.01%$0 MOct 20, 2026
79Legal & General Group Plc4,5640 (0.00%)0.01%$0 MNov 16, 2026
80Ameritas Investment Partners, Inc.4,2830 (0.00%)0.01%$0 MNov 13, 2026
81Russell Investments Group, Ltd.4,0240 (0.00%)0.01%$0 MNov 6, 2026
82NewEdge Advisors, LLC3,5000 (0.00%)0.01%$0 MNov 13, 2026
83Mirae Asset Global Investments Co., Ltd.2,936+373 (+14.55%)0.01%$0 MOct 29, 2026
84Royal Bank Of Canada2,453+953 (+63.53%)0.00%$0 MNov 16, 2026
85Allworth Financial LP2,151New0.00%$0 MNov 17, 2026
86Parkside Financial Bank & Trust2,112New0.00%$0 MOct 27, 2026
87Arax Advisory Partners2,029+2,020 (+22444.44%)0.00%$0 MNov 12, 2026
88Optiver Holding B.V.1,959-5,579 (-74.01%)0.00%$0 MNov 16, 2026
89GF Fund Management Co. LTD.1,290+105 (+8.86%)0.00%$0 MOct 26, 2026
90GAMMA Investing LLC1,227New0.00%$0 MOct 8, 2026
91Federated Hermes, Inc.1,096-2,207 (-66.82%)0.00%$0 MNov 12, 2026
92Sterling Capital Management LLC901-50 (-5.26%)0.00%$0 MOct 22, 2026
93SJS Investment Consulting Inc.882New0.00%$0 MOct 26, 2026
94Global Retirement Partners, LLC677New0.00%$0 MNov 10, 2026
95Osaic Holdings, Inc.4800 (0.00%)0.00%$0 MNov 12, 2026
96Farther Finance Advisors, LLC430New0.00%$0 MOct 8, 2026
97Jones Financial Companies Lllp4280 (0.00%)0.00%$0 MNov 13, 2026
98EverSource Wealth Advisors, LLC366New0.00%$0 MNov 4, 2026
99Rothschild Investment LLC325New0.00%$0 MNov 10, 2026
100Federation des caisses Desjardins du Quebec2800 (0.00%)0.00%$0 MNov 16, 2026

All 111 institutional investors, with who bought and sold →

Mutual funds holding Black Diamond Therapeutics, Inc.#

81 funds hold shares worth $20 M (about 19.3% of the company). Since their previous reports 51 added shares and 27 sold, selling $4 M net.
Mutual funds holding Black Diamond Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 T. Rowe Price Small-Cap Value Fund, Inc.T. Rowe Price Associates, Inc.2.12 M$4 M3.7%0.04%−0.5%Jun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.56 M$3 M2.7%<0.01%+20%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.21 M$2 M2.1%<0.01%newJun 30, 2026
🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC521,043$1 M0.91%0.02%+11%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.511,250$1 M0.89%<0.01%+3.1%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC513,120$1 M0.89%<0.01%newJul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors465,655$1 M0.81%<0.01%newJun 30, 2026
🇺🇸 iShares U.S. Small-Cap Equity Factor ETFBlackRock Fund Advisors469,215$1 M0.82%0.02%+118%Jul 31, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors347,116$1 M0.60%<0.01%+8.0%Jun 30, 2026
🇺🇸 U.S. Small Cap Value PortfolioDimensional Fund Advisors LP341,219$1 M0.59%<0.01%+36%Jul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC240,495$1 M0.42%<0.01%+0.8%May 31, 2026
🇺🇸 EA Bridgeway Omni Small-Cap Value ETFEmpowered Funds, LLC d/b/a EA Advisers248,134$0 M0.43%0.02%+7.8%Jun 30, 2026
🇺🇸 Dimensional US Small Cap Value ETFDimensional Fund Advisors LP210,208$0 M0.37%<0.01%+31%Jul 31, 2026
🇺🇸 Small Cap Value PortfolioMason Street Advisors, LLC182,571$0 M0.32%0.05%−9.4%Jun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors159,482$0 M0.28%0.02%+35%Jun 30, 2026
🇺🇸 T. Rowe Price Spectrum Moderate Growth Allocation FundT. Rowe Price Associates, Inc.96,029$0 M0.17%<0.01%+2.3%May 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.113,822$0 M0.20%<0.01%newJul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC78,981$0 M0.14%<0.01%no changeMay 31, 2026
🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc.93,180$0 M0.16%0.01%no changeJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust73,654$0 M0.13%<0.01%no changeMay 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC88,223$0 M0.15%<0.01%newJun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC88,000$0 M0.15%0.11%no changeJun 30, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC94,181$0 M0.16%<0.01%−9.4%Jul 31, 2026
🇺🇸 WisdomTree U.S. SmallCap FundWisdomTree Asset Management, Inc.85,380$0 M0.15%0.02%−2.3%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC67,272$0 M0.12%<0.01%+6.4%May 31, 2026
🇺🇸 Omni Small-Cap Value FundBridgeway Capital Management, LLC70,000$0 M0.12%<0.01%no changeJun 30, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP74,316$0 M0.13%<0.01%−61%Jul 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC65,660$0 M0.11%<0.01%newJun 30, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP69,382$0 M0.12%<0.01%−1.1%Jul 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC64,801$0 M0.11%<0.01%newJul 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP62,435$0 M0.11%<0.01%−67%Jul 31, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC53,319$0 M0.09%0.01%−38%Jun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC52,616$0 M0.09%<0.01%newJun 30, 2026
🇺🇸 Small Company Value TrustJohn Hancock Variable Trust Advisers LLC40,600$0 M0.07%0.05%no changeJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC32,498$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation38,400$0 M0.07%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Spectrum Moderate Allocation FundT. Rowe Price Associates, Inc.31,074$0 M0.05%<0.01%−12%May 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP35,761$0 M0.06%<0.01%−48%Jul 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.30,769$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.27,000$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 T. Rowe Price Spectrum Conservative Allocation FundT. Rowe Price Associates, Inc.21,171$0 M0.04%<0.01%−8.9%May 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.21,836$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC23,643$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC22,531$0 M0.04%<0.01%newJul 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.20,201$0 M0.04%<0.01%−34%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC16,658$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC16,170$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC16,170$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Value ETFAmerican Century ETF Trust12,801$0 M0.02%<0.01%newMay 31, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC15,807$0 M0.03%<0.01%−1.1%Jul 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.14,484$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC11,160$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS11,008$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC10,787$0 M0.02%<0.01%+23%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC10,772$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS9,304$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC7,818$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors7,701$0 M0.01%<0.01%−22%Jun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC7,559$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC8,280$0 M0.01%<0.01%+20%Jul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.7,305$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.7,200$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity FundAmerican Century ETF Trust4,591$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC5,527$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.5,320$0 M<0.01%<0.01%+3.9%Jul 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS5,128$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc.4,590$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management4,283$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC3,774$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC3,559$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC3,843$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC3,390$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC3,325$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC1,700$0 M<0.01%<0.01%+325%May 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.2,000$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC1,828$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.1,613$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC1,136$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC1,090$0 M<0.01%<0.01%−6.1%Jun 30, 2026
🇺🇸 Dimensional VA U.S. Targeted Value PortfolioDimensional Fund Advisors LP968$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC298$0 M<0.01%<0.01%+32%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 81 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Black Diamond Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
27
since
-$12.0 M$0Aug 2024: bought $0 (0 trades), sold $1.4 M (1 trades)Aug 24Mar 2025: bought $0 (0 trades), sold $12.0 M (7 trades)Mar
Bought (open market)Sold (open market)Hover a month for the totals
Black Diamond Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Prakash RamanDirectorGrant or award+6,801$1.930$13 K51,840Form 4
filed Ali BehbahaniDirectorGrant or award+7,707$1.930$15 K110,236Form 4
filed Ali BehbahaniDirectorGrant or award+8,961$1.660$15 K102,529Form 4
filed Prakash RamanDirectorGrant or award+7,907$1.660$13 K45,039Form 4
filed Ali BehbahaniDirectorGrant or award+6,919$2.150$15 K93,568Form 4
filed Prakash RamanDirectorGrant or award+6,105$2.150$13 K37,132Form 4
filed Ali BehbahaniDirectorGrant or award+5,208$2.760$14 K86,649Form 4
filed Prakash RamanDirectorGrant or award+4,665$2.760$13 K31,027Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Black Diamond Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
5.1 M
8.9% of shares · 4.87 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 3.016-for-1 split

Trading halts

  • 2025-12-03 14:33 UTC, code LUDP, resumed 14:43 UTC

Fails to deliver

  • : 12,177 shares at $1.88
  • : 4,385 shares at $2.08
  • : 2,795 shares at $1.68
  • : 7,117 shares at $1.94
  • : 934 shares at $1.87

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Black Diamond Therapeutics, Inc. scorecard#

Passes 10 of the 15 checks that could be worked out: strongest in valuation (4 of 5), weakest in financial health (1 of 3). Fiscal year 2025; market cap of Oct 26, 2026.

  • Valuation4 of 5
    • ✓P/E below its peers' median4.8×P/E 4.8× against Biotechnology's median of 17.5×.
    • ✓Price to book below its peers' median1.0×Price to book 1.0× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median1.5×Price to sales 1.5× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-57.7%Free cash flow is -57.7% of the market value.
    • ✓Earnings yield above the 10-year Treasury yield20.7%Earnings yield 20.7% against the 10-year Treasury's 5.15% on 2026-11-13.
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth2 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✓Earnings per share grew in the newest year0.39 vs -1.27Diluted EPS 0.39 in fiscal 2025 against -1.27 the year before (report's currency).
    • ✓Net income higher than five years earlier$22 M$22 M in fiscal 2025 against -$67 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability3 of 4
    • ✓Profitable in the newest year$22 MNet income $22 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median17.9%17.9% against Biotechnology's median of -60.5% (243 companies).
    • ✓Return on equity above 15%22.9%22.9% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities8.4×Current ratio 8.42 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-0.69Z-score -0.69 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year4.6%Diluted shares up 4.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Black Diamond Therapeutics, Inc.'s statements, beside the median of Biotechnology.

Black Diamond Therapeutics, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin17.9%-60.5%
Net margin32.0%-68.9%
Return on equity22.9%-61.0%

5of 6on the Piotroski tests of financial strength

Black Diamond Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Black Diamond Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018
Income statement
Revenue700———000
Research and development345159649748227.0
General and administrative1727272830217.62.0
Operating expenses5779869312770298.9
Operating income13−79−86−93−127−70−29−8.9
Interest expense and finance costs————00.00—
Share of profit of associates——0−2.30———
Other non-operating income (expense)9.89.14.03.91.32.3−5.9−0.0
Income tax00000000
Net income attributable to shareholders22−70−82−91−126−67−35−8.9
Earnings per share, basic0.39-1.27-1.88-2.52-3.47-2.05-16.99-4.42
Earnings per share, diluted0.39-1.27-1.88-2.52-3.47-2.05-16.99-4.42
Shares, weighted average (basic)575544363633——
Shares, weighted average (diluted)5855443636332.12.0
Balance sheet
Cash and cash equivalents21365634663515552
Short-term investments1086275881442800—
Other current assets3.82.62.64.95.94.51.00.0
Current assets13210113412821632015652
Property, plant and equipment0.41.41.72.63.00.40.20.1
Right-of-use (leased) assets9.3192225288.4——
Total assets14312315915624833015852
Accounts payable0.64.02.31.94.12.52.00.4
Current liabilities1621201524144.92.6
Lease liabilities (non-current)15192225287.7——
Total liabilities3139424152224.96.6
Retained earnings−465−487−417−335−244−118−51−16
Shareholders' equity11283117116196308−47−16
Total liabilities and equity14312315915624833015852
Shares outstanding5757523636362.22.2
Cash-flow statement
Share-based compensation6.6119.612147.83.60.1
Cash from operating activities30−62−67−85−100−52−25−8.5
Capital expenditure—0−0.0−0.2−2.7−0.1−0.0−0.1
Cash from investing activities−45171653131−282−0.0−0.1
Shares issued024720————
Cash from financing activities−0.126720.20.721512852
Change in cash−15−2022−3231−11910344
Report10-K10-K10-K10-K10-K10-K10-K10-K

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Black Diamond Therapeutics, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Reportable segment$70 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Black Diamond Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.2 M
Dr. Velleca
Other top executives, average
$1.3 M
the CEO earned 1.7× this
$100 invested is now
$89
Black Diamond Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. Velleca$2.2 M$2.6 M$1.3 M$89
2024Mark A. Velleca$2.9 M$1.9 M$1.5 M$76

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Black Diamond Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 3 · Material agreement 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 13

Black Diamond Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Bylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

4 private funding rounds before listing

Private share sales · funding history

Private share sales of Black Diamond Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2019$85 MNo. 4$50 to $250 million28equitySEC
Dec 2018$44 MNo. 3$10 to $50 million16equitySEC
Aug 2018$5 MNo. 2$2 to $10 million1equitySEC
Mar 2017$12 MNo. 1$10 to $50 million11equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Black Diamond Therapeutics, Inc. compares in Biotechnology

  • Market cap$108 M · higher than 37% of 726
  • Revenue$70 M · higher than 64% of 647
  • Net margin32.0% · higher than 92% of 408
  • P/E ratio4.8× · lower than 85% of 100
  • Price / sales1.5× · lower than 90% of 339
  • Price / book1.0× · lower than 80% of 534
  • FCF yield-57.7% · higher than 21% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Black Diamond Therapeutics, Inc.🇺🇸$108 M4.8×32.0%—
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 26, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on January-2020
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Black Diamond Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Black Diamond Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Black Diamond Therapeutics, Inc.? Suggest a correction